Pharmacy company Amber Specialty Pharmacy announced on Friday that it commenced administering the doses of new US FDA-approved infusion antibody treatment bamlanivimab (BAM) to long-term care facilities in Des Moines, Chicago, Buffalo, Phoenix and Dallas across the US to combat COVID-19 under a partnership with the US Department of Health and Human Services and the National Home Infusion Association.
The company added the purpose of the pilot programme is to expand access to a safe and effective treatment to the most vulnerable population across the country. The BAM pilot programme requires providers to be accredited and licensed to perform home infusions.
Bamlanivimab is a monoclonal antibody developed by Eli Lilly and received emergency FDA approval in November 2020. The infusion therapy is a tiered approach designed for high-risk patients who have the potential to develop severe complications from COVID-19.
While certain therapies and antiviral drugs used in hospitals inhibits the replication of the virus and shorten the course of the infection, BAM reportedly boosts the patient's own immune response to help fight the infection and prevent complications that would result in hospitalization, concluded the company.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML